PMV Pharma Shares Surge on Promising Clinical Data

PMV Pharmaceuticals shares are trading higher after the company announced promising interim data from its Phase 2 PYNNACLE trial, highlighting the efficacy of rezatapopt in treating solid tumors with a TP53 Y220C mutation.